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Abstract
Obtaining suitable seed viruses for influenza vaccines poses a challenge for public health authorities and 
manufacturers. We used reverse genetics to generate vaccine seed-compatible viruses from the 2009 pandemic swine-
origin influenza virus. Comparison of viruses recovered with variations in residues 186 and 194 (based on the H3 
numbering system) of the viral hemagglutinin showed that these viruses differed with respect to their ability to grow in 
eggs and cultured cells. Thus, we have demonstrated that molecular cloning of members of a quasispecies can help in 
selection of seed viruses for vaccine manufacture.
Findings
In the spring of 2009, a novel type A influenza virus of
swine origin (S-OIV) bearing an H1 hemagglutinin (HA)
and an N1 neuraminidase (NA) was isolated from acutely
ill humans [1]. Unlike some novel influenza strains, such
as recent H5N1 strains of avian origin, S-OIV is not
highly pathogenic [2]. However, it is readily transmissible
and has spread globally in a new pandemic. Young people
and those with medical conditions, such as asthma, are at
particularly high risk for morbidity and mortality from S-
OIV [3]. The public health response to the emergence of
S-OIV has been swift, with the rapid manufacture, test-
ing, and distribution of monovalent pandemic vaccines
and inclusion of the pandemic strain in the trivalent vac-
cine composition recommended for use in the 2010
southern hemisphere seasonal immunization campaign.
One of the great challenges to influenza vaccine manu-
facture is the rapid generation of safe and well growing
seed viruses that are antigenically matched with newly
emerged strains. Currently, selection of seasonal type A
vaccine strains relies on a network of laboratories that
generate classical reassortant viruses in eggs. To make
these reassortants, the protective HA and NA determi-
nants are swapped through mating onto the genetic back-
ground of a virus that grows to high titers in eggs. This
method creates significant genetic bottlenecks and can
produce variants with egg-adapted HA mutations that
alter antigenic properties, making them unacceptable for
use as vaccine seeds (see more below). The selection of
variants under these circumstances undoubtedly relates
to the quasispecies nature of the virus used to derive
these reassortants.
Reassortants can also be generated by reverse genetics
technology, in which viable infectious virus is rescued
from cells transfected with plasmid DNAs encoding the 8
influenza virus genome segments [4,5]. For example,
reverse genetics has been used in human vaccine manu-
facture to generate seeds for vaccines against highly
pathogenic H5N1 avian-origin influenza viruses. Since
these wild-type, high-pathogenicity avian strains kill the
chick embryos used for manufacture, an engineered
modification to the HA of these strains was used to lower
their pathogenicity, permitting vaccine production in
eggs [6].
Here, we describe the rescue of reverse genetics reas-
sortants that carry the NA gene and one of three different
HA genes derived from the A/California/04/2009
(termed A/CA/04/2009) isolate of S-OIV on a standard
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vaccine-compatible genetic background (A/PR/8/34).
The three HA variants are members of the quasispecies
represented in the RNA prepared from this A/CA/04/
2009 clinical isolate that had been passed once in Madin
Darby canine kidney (MDCK) cells. The different growth
properties of the three rescued reassortants indicate that
a reverse genetics seed development process that takes
advantage of the natural diversity represented in influ-
enza virus quasispecies may have advantages over meth-
ods (such as classical reassortant methods) that examine
clonally derived virus strains for their utility as high yield-
ing seeds for vaccine manufacture.
Our reverse genetics system is based on the dual-pro-
moter plasmid system in which the A/PR/8/34 PB1, PB2,
PA, NP, M and NS genes were cloned into the pHW2000
plasmid (or a plasmid with similar genetic elements)
using universal primers [7]. In this system, the resulting
plasmids contain influenza virus sequences that are tran-
scribed from a cytomegalovirus (CMV) immediate early
promoter to make mRNAs for protein expression and
from a short version of the human RNA polI promoter to
make negative-sense RNAs that can be replicated by the
viral RNA-dependent RNA polymerase to form influenza
virus genome segments [8]. Preliminary studies demon-
strated that our plasmid system could generate reverse
genetics influenza viruses in both human cells (293T) and
in a derivative of MDCK cells that had been adapted to
growth in suspension for vaccine manufacture [9]. Viral
RNA (prepared from virus passaged twice in MDCK cells
by using the QIAamp Viral RNA Mini Kit) was converted
to cDNA using the Monsterscript reverse transcriptase
(Epicentre Biotechnologies) and then amplified by over-
lap PCR using the Herculase polymerase (Stratagene) to
create genomic segments corresponding to the posted
sequence of this isolate [GenBank: GQ117044] and
restriction sites compatible with the pHW2000 plasmid
[7] (Oligonucleotide sequences are available from the
authors upon request). BsmBI-digested PCR fragments
were ligated to an appropriately digested pHW2000 vec-
tor DNA and transformed into E.coli. Ampicillin-resis-
tant colonies were selected and screened by PCR and
used without further analysis or re-streaking.
Sequencing of RT-PCR amplified cDNA from A/CA/
04/2009 (a strain of S-OIV) revealed a quasispecies in the
HA gene, with clearly detectable heterogeneity in codons
186 and 194. Reassortant viruses were rescued by trans-
fecting 293T or MDCK cells with plasmids encoding S-
OIV HA and NA, the remaining six genome segments
from A/PR/8/34, and the gene for TMPRSS2 serine pro-
tease [10] to help amplify rescued viruses. The NA used
for the rescue differs from the posted A/CA/04/2009 NA
sequence [GenBank: FJ969517] by a single mutation,
which results in a N2S amino acid substitution. This
mutation represents a natural existing variant of the virus
that was amplified by chance. The three different A/CA/
04/2009 HA-encoding plasmids used in the transfections
represented different clones of the A/CA/04/2009 HA
quasispecies: plasmid F8 encodes P186 and L194; plasmid
F9 encodes S186 and I194; and plasmid F10 encodes S186
and L194, which matches the posted sequence [GenBank:
GQ117044] (Fig. 1). These positions are based on the H3
numbering system.
Transfection of either 293T or MDCK cells with plas-
mid cocktails containing any of the HA variants produced
reassortant viruses. Recovery in 293T cells was more effi-
cient than in MDCK cells, with higher titers detectable in
the original transfection supernatant. However, with
modified recovery methods [9], all transfections pro-
duced virus from each of the HA plasmid DNAs. No
infectious virus was recovered from any simultaneous
control transfections with plasmid mixtures lacking a HA
gene. Sequence analyses of HA and NA genes of the
viruses rescued from the plasmid DNAs revealed that
they faithfully retained sequences of the parental plasmid
DNA (see Fig. 1).
Growth of the three reassortants (vF8, vF9, and vF10)
was compared to the growth of wild type S-OIV and A/
PR/8/34 in MDCK cells (Fig 2a and 2b) and embryonated
chicken eggs (Fig 2c and 2d). Virus titer was assayed by
formation of infectious foci on MDCK cells (focus forma-
tion assay - FFA) and guinea pig red blood cell agglutina-
tion (hemagglutination assay - HA). The wild-type S-OIV
used for these studies was precisely the same virus used
to produce the cloned plasmid DNAs, and it had been
passaged only twice in MDCK cells. Interestingly, it pro-
duced approximately 10,000-fold less infectious virus on
MDCK cells than it did in eggs (Fig. 2a and 2c), although
it produced similar HA activity in eggs and MDCK cells
(Fig. 2b and 2d). The A/PR/8/34 strain used in these stud-
ies was derived from an egg-passaged isolate that had
been extensively passaged in MDCK cells and grew to
Figure 1 Alignment of amino acid sequences of the S-OIV H1 HA 
with the H3 prototype HA in the region near the sialic acid bind-
ing site. Protein sequences translated from the deposited S-OIV A/CA/
04/2009 sequence [GenBank: GQ117044] are shown under the proto-
type of the H3 subtype from human (A/HongKong/1/68) strain se-
quence [PDB: 1HGD]. Below these are the sequences detected in cDNA 
amplified from A/CA/04/2009 RNA, with the prominent quasispecies 
at positions 186 and 194 indicated by "X," and three plasmid DNAs 
cloned from this quasispecies. Underlining indicates variations from 
the posted sequence.Suphaphiphat et al. Virology Journal 2010, 7:157
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approximately 10-fold lower infectious titer in MDCK
cells than in eggs (Fig. 2a and 2c)
The three reverse genetics reassortants rescued with
different HA variants had reproducibly different growth
characteristics when propagated in MDCK cells and eggs.
The F10 variant was significantly less productive than F8
and F9 by both infectious and HA assays in MDCK cells
and in eggs (Fig 2a-d). The F8 variant grew to approxi-
mately 10-fold higher infectious titer and produced more
than 4-fold greater HA activity than the other reverse
genetics reassortants in MDCK cells (Fig. 2a and 2b),
although its performance was comparable to that of the
F9 variant in eggs (Figs. 2c and 2d). These data indicate
that the quasispecies variation in HA affects growth char-
acteristics relevant for vaccine seed suitability.
To determine if the HA mutations at positions 186 and
194 altered the antigenicity of HA, this panel of viruses
was subjected to the hemagglutination inhibition assay
(HAI) using ferret antisera against A/CA/04/2009, A/CA/
07/2009, or RG-15 (a reverse genetics-derived A/TX/05/
2009-like strain). Deposited sequences for A/CA/04, A/
CA/07, and RG-15 HA [GenBank: GQ117044, FJ969540,
and GQ457487, respectively) give identical amino acid
sequences from residues 87 to 199 (H3 numbering). The
HAI titers of all of these antisera with each of our reverse
genetics variants were greater than or equivalent to those
obtained with A/CA/04/2009, whereas reaction of these
variants with normal ferret sera or reaction of A/PR/8/34
virus with these test sera were undetectable (Table 1).
Thus, all of our reverse genetics viruses were antigeni-
cally similar to the parental A/CA/04/2009 and A/CA/
07/2009 viruses despite the presence of point mutations
that improved growth. However, a reverse genetics virus
equivalent to F8 with an additional N159 D mutation,
Figure 2 Yield of A/CA/04/2009, A/PR/8/34, and reverse genetics viruses bearing the A/CA/04/2009 NA and selected HA genes, as de-
scribed in Fig. 1. A. Infectious titer of virus produced by MDCK cell monolayers infected at an MOI of 0.05 in 6-well plates, as determined by focus 
formation assay (FFA) on MDCK cells [21]. Cells were incubated at 37°C for the indicated times, after which 200 μl of the culture medium was sampled 
and stored at 4°C for infectious titer determination on MDCK cells using a slight modification of previously described FFA methods [21]. Data shown 
are the mean and standard deviation (S.D.) from one of three representative experiments. B. HA titers of MDCK-derived virus samples collected from 
the experiment in panel A, determined using standard methods [22]. Data shown are from one of three representative experiments. C. Infectious titers 
of virus produced by twelve- to fourteen-day-old embryonated chicken eggs infected with 100 μl of the indicated virus stocks containing 10,000 in-
fectious units (as determined by FFA). The eggs were incubated for 72 hrs at 34°C after infection, and titers were determined as described for panel A. 
Mean and S.D. from four independent experiments are shown, with 2-4 eggs used for each virus in each experiment. D. HA titers of egg-derived virus 
samples collected from the experiment in panel C. Mean and S.D. from four independent experiments are shown.
A B A. B.
C. D.
1Suphaphiphat et al. Virology Journal 2010, 7:157
http://www.virologyj.com/content/7/1/157
Page 4 of 5
which increases growth in eggs but decreases HAI titer,
had 8-fold lower HAI titer than A/CA/04 (data not
shown); thus, demonstrating that some mutations in S-
OIV HA can simultaneously alter growth and antigenic
structure, confounding vaccine manufacture.
Examination of the electropherograms prepared from
sequencing reactions created with the RNA recovered
from wild type (non-reassortant) S-OIV virus harvested
at late time points in MDCK growth from a similar exper-
iment failed to reveal a detectable change in the propor-
tion of the various HA genotypes within the quasispecies.
The stability of HA quasispecies distribution in the wild
type virus despite significant variation in the growth of
reassortants prepared from individual HA clones selected
from the quasispecies suggests that molecular cloning of
individual variants can accelerate adaptation to growth in
new conditions. In this study, we have demonstrated the
utility of cloning members of the quasispecies in generat-
ing a potential vaccine seed derived by methods compati-
ble with manufacture in vaccine-approved MDCK cells.
The variable 186 and 194 residues are immediately
adjacent to the sialic acid binding site, based on a model
we created by modeling the sequence A/CA/04/2009 HA
onto the structure determined for the H1 HA from a 1918
pandemic strain of influenza virus [11] (Fig. 3). There-
fore, these residues could affect cell attachment, substrate
specificity, growth characteristics, and red blood cell
agglutination. Similar mutations in H1N1 swine flu iso-
lates from the 1970 s increase growth in eggs and MDCK
cells and reduce growth in swine [12]. Other groups have
also demonstrated positive selective pressure on a variety
of residues near the receptor binding site in H3N2 iso-
lates, including variations at the same residues (186 and
194) [13-15] that we detected in our H1 S-OIV quasi-spe-
cies. More recently, Glaser et al. showed that a mutation
at a nearby position (190) in the HA of the avian H1N1
virus that caused the 1918 pandemic was associated with
this strain's adaptation to humans [16].
The HA sequence variants we detected in the A/CA/
04/2009 isolate were not reported in two recent studies
that examined variation in residues near the receptor
binding pocket of many S-OIV isolates [17,18]. However,
during the time this manuscript was being prepared,
Table 1: Effect of variations at residues 186 and 194 of A/CA/04/2009 HAs on reactivity with post-infection ferret sera
HAI titer with selected ferret sera1
Virus designation RG15 A/CA/04 A/CA/07 Normal
vF8 320, 6402 1280, 2560 1280, 2560 <40, <40
vF9 160, 320 640, 1280 640, 1280 <40, <40
vF10 320, 320 5120, 2560 5120, 2560 <40, <40
A/CA/04/2009 160, 160 640, 640 640, 640 <40, <40
A/PR/8/34 <40, <40 <40, <40 <40, <40 <40, <40
1 H1N1 immune ferret sera were obtained from CDC. Ferrets were infected with RG15 (IDCDC RG15, a reverse genetics virus containing the 
A/TX/05/2009 HA [A/TX/05/2009 × A/PR/8/34], A/CA/04 (A/CA/04/2009, Lot # 2009-082, CDC#2009712049), or A/CA/07 (A/CA/07/2009, Lot 
#2009-089, CDC#2009712112). Normal (un-infected ferret) sera was obtained from Alpha Diagnostics Intl., Inc.
2 Data shown are from two experiments in which all four sera were checked in parallel with all five antigens.
HAI tests were performed by standard methods using guinea pig red blood cells, receptor-destroying enzyme-treated serum, and 4 HA units 
of antigen [25].
Figure 3 Surface representation of A/CA/04/2009 HA modeled on 
the known structure of 1918 HA [PDB: 1RUZ] with a sialoside 
bound at the active site (based on alignment to PDB: 1RVT) [11]. 
HA1 is shown in various shades of gray, HA2 in orange, and glycan 
modification of HA in brown. The bound sialoside is modeled as a ball-
and-stick representation with yellow carbons and red oxygens. The po-
sitions of Ser186 (yellow) and Leu194 (red) are highlighted. The model 
was generated and the structure aligned with O [23], and the figure 
was generated with Chimera [24].Suphaphiphat et al. Virology Journal 2010, 7:157
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Chen et al. identified some natural HA variants (includ-
ing L194I, but not S186P) in A/CA/04/2009 that
improved virus recovery in MDCK/293 cells [19]. Carbo-
hydrate microarray data do demonstrate differences in
sialic acid specificity between S-OIV isolates that differ at
several HA residues [20], suggesting that genetic pressure
could be exerted on the receptor binding pocket of S-OIV
during isolation on MDCK cells. Our data provide addi-
tional documentation of the importance of HA residues
near the receptor binding pocket in the adaptation of
viruses to growth in vitro. Because some of the variants
increase the growth of S-OIV reassortants in mammalian
cells and eggs, these results demonstrate that sampling
viral quasispecies during the rescue of reassortant viruses
by reverse genetics can identify useful isolates for vaccine
manufacture.
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